These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28813219)

  • 1. Association of Reference Pricing with Drug Selection and Spending.
    Robinson JC; Whaley CM; Brown TT
    N Engl J Med; 2017 Aug; 377(7):658-665. PubMed ID: 28813219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician and Patient Adjustment to Reference Pricing for Drugs.
    Robinson JC; Whaley C; Brown TT; Dhruva SS
    JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Reference Pricing for Diagnostic Laboratory Testing With Changes in Patient Choices, Prices, and Total Spending for Diagnostic Tests.
    Robinson JC; Whaley C; Brown TT
    JAMA Intern Med; 2016 Sep; 176(9):1353-9. PubMed ID: 27454826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reference Pricing, Consumer Cost-Sharing, and Insurer Spending for Advanced Imaging Tests.
    Robinson JC; Whaley C; Brown TT
    Med Care; 2016 Dec; 54(12):1050-1055. PubMed ID: 27479594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
    Raimond VC; Feldman WB; Rome BN; Kesselheim AS
    Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.
    Grootendorst PV; Dolovich LR; O'Brien BJ; Holbrook AM; Levy AR
    CMAJ; 2001 Oct; 165(8):1011-9. PubMed ID: 11699696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
    Sheingold S; Nguyen NX
    Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
    Schneeweiss S; Walker AM; Glynn RJ; Maclure M; Dormuth C; Soumerai SB
    N Engl J Med; 2002 Mar; 346(11):822-9. PubMed ID: 11893794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reference Pricing Changes The 'Choice Architecture' Of Health Care For Consumers.
    Robinson JC; Brown TT; Whaley C
    Health Aff (Millwood); 2017 Mar; 36(3):524-530. PubMed ID: 28264955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What Determines How Much Your Patient Pays for Their Medication in the United States?
    Novack GD
    Am J Ophthalmol; 2016 Jul; 167():48-51. PubMed ID: 27131775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
    N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription drugs: issues of cost, coverage, and quality.
    Copeland C
    EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards.
    Bendicksen L; Rome BN; Avorn J; Kesselheim AS
    Milbank Q; 2021 Dec; 99(4):1162-1197. PubMed ID: 34375015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.
    Schneeweiss S; Soumerai SB; Glynn RJ; Maclure M; Dormuth C; Walker AM
    CMAJ; 2002 Mar; 166(6):737-45. PubMed ID: 11944760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of a three-tier formulary on antidepressant utilization and expenditures.
    Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
    J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.